Search Results

Geistlich Pharma North America Inc. is pleased to announce that our Executive Chairman, Dr. Andreas Geistlich, has been awarded the prestigious American Association of Oral and Maxillofacial Surgeons Board of Trustees Special Citation Award for the company’s exceptional and longstanding contributions to the field of Oral and Maxillofacial Surgery.

Geistlich Pharma North America Inc. is setting the pace for expanded treatment options with the introduction of vallos™, our first demineralized allograft.

Geistlich Pharma North America announced today the acquisition of Lynch Biologics, LLC, the developer and sole provider of GEM 21S®, the first recombinant growth factor product for use in oral regenerative surgery.

The Geistlich Surgery, USA business unit of Geistlich Pharma AG, a family owned, Swiss-based global leader in regenerative solutions, is proud to announce the launch of its latest advancement: Geistlich Nexo-Gide® Dual Surface Membrane.

Celularity Inc. announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline.

Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications.